ProfileGDS5678 / 1449912_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 42% 43% 40% 42% 42% 49% 42% 41% 43% 42% 42% 45% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1053145
GSM967853U87-EV human glioblastoma xenograft - Control 22.9775942
GSM967854U87-EV human glioblastoma xenograft - Control 32.9901343
GSM967855U87-EV human glioblastoma xenograft - Control 42.8606640
GSM967856U87-EV human glioblastoma xenograft - Control 52.9150542
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0672842
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2565449
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9587642
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9239241
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9779243
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9724342
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9404742
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0562145
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9791143